Dear readers of, please forgive the disruption. needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find useful, please take a minute and support with your donation. Thank you!

Since 01.06.2021 is supported by the non-profit ADxS e.V..

$27450 of $36850 - as of 2023-11-30
Header Image
Ropinirole for ADHD


Ropinirole for ADHD

Ropinirole is a non-ergot dopamine agonist.
Ropinirole is a selective D2 agonist.

Ropinirole is commonly used as a Parkinson’s disease medication.

A small prospective study tested ropinirole for ADHD in 9 boys aged 8 to 13 years.1
In 33% of the subjects (2 out of 6), there was a very significant improvement in concentration.
In 84% of subjects (5 of 6), ropinirole improved impulsivity and the number of errors on the CPT between low to significant. In 50% of subjects (3 of 6), the improvement in the number of errors was at least 40% of the baseline number of errors without medication. In terms of impulsivity, ropinirole was found to be on par with MPH.

The number of subjects in this study is far too small to draw reliable conclusions. However, the results indicate that ropinirole could be a helpful tool to improve concentration and impulsivity in individual sufferers. In particular, in MPH and AMP nonresponders, ropinirole could be considered for an individual remedy trial. An individual case report of a 6-year-old boy with ADHD and restless legs who was an MPH nonresponder showed a good effect of ropinirole on ADHD and RLS.2

Ropinirole showed severe daytime sleepiness as a side effect, which was even more severe at 2 mg/day (3 of 3 subjects) than at 1 mg/day (4 of 6 subjects).
This may indicate that ropinirole may be helpful for sleep problems in ADHD.

Diese Seite wurde am 13.03.2023 zuletzt aktualisiert.